ArticlePloS one2026
In silico framework for designing and validating a multi-stage subunit vaccine against Tuberculosis using reverse vaccinology approach.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a critical public health concern due to the limited efficacy of the Bacillus Calmette-Guerin (BCG) vaccine, the only WHO-approved vaccine so far. Based on the reverse vaccinology approach, this study involves in silico prediction of a fusion constructed from four highly immunogenic antigens from the latent, early, and active stages of the disease. The fusion named TetraFuVac11 consists of the complete sequences of the antigens CFP-7 and EspC and the truncated sequences of the antigens HspX and Hrp1. Major Histocompatibility Complex II (MHC II) binding Th-cell-specific epitopes were predicted through tools provided in the Immune Epitope Database (IEDB). The designed fusion molecule was found to be antigenic, non-allergenic and non-toxic. The instability index II and the GRAND Average of Hydropathy values were predicted to be 29.51 and -0.182, respectively. The refinement of the predicted 3D structure resulted in an improved stereochemical profile. The Z-score was predicted to be -6.8, and the ERRAT score was improved from 94.928 for the unrefined model to 97.1591 for the refined model. The data obtained from molecular dynamics (MD) simulations and Normal Mode Analysis (NMA) of the docked complex between the refined fusion protein and Toll-like Receptor 4 (TLR4) demonstrated a s interaction. The fusion construct was successfully predicted to be cloned into the pET-28a(+) vector to make a recombinant plasmid. The predicted solubility of the fusion protein exceeded the threshold values, indicating soluble expression in Escherichia coli. Finally, based on the encouraging in silico data, the proposed construct could serve as a potential vaccine candidate for detailed experimental validation towards developing an Mtb-specific vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.